share_log

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target

HC Wainwright & Co.重申买入 Capricor Therapeutics,维持18美元的目标价格
Benzinga ·  2023/03/16 06:18

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $18 price target.

HC Wainwright&Co.分析师约瑟夫·潘特吉尼斯重申纳斯达克(Capricor Treateutics)的买入,并维持18美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发